logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marina Elena Cazzaniga

University of Milano-Bicocca
H指数:46
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review

多内分泌免疫相关不良事件(irAEs)与帕博利珠单抗作为新辅助治疗在两例TNBC患者中的相关性：病例报告与文献综述

Current Oncology
IF3.4
2026-03-040
OAAI
Khashayar Yazdanpanah Ardakani; Gaia Passarella; Andrea Gerardo Antonio Lania; Thoma Dario Clementi; Alessandro Fanti; Francesca Fulvia Pepe; Serena Capici; Marina Elena Cazzaniga
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial

一项评估阿贝西利联合芳香化酶抑制剂（AIs）作为一线氟维司群后二线治疗的活性与安全性的2期、开放标签、多中心、单臂试验，适用于激素受体阳性（HR+）、人表皮生长因子受体阴性（HER2-）转移性乳腺癌（MBC）患者。HERMIONE-7试验的最终结果。

Clinical Breast Cancer
IF2.5
2025-05-130
PRE
Cazzaniga Marina Elena; Pepe Francesca Fulvia; Rossi Emanuela; Coltelli Luigi; Beano Alessandra; Valerio Maria Rosaria; Ferro Antonella; Zustovich Fable; Moretti Gabriella; Toniolo Davide; Cordani Nicoletta; Galimberti Stefania; Capici Serena
Selection criteria for second-line treatments after Cyclin-dependent kinase 4/6 inhibitors failure in Hormone Receptor positive metastatic breast cancer patients: the preliminary experience of the HERMIONE-13 trial
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Cazzaniga, Marina Elena; Rossi, Emanuela; Turla, Antonella; Ambroggi, Massimo; Baggi, Alice; Berardi, Rossana; Borella, Fulvio; Capici, Serena; Cicchiello, Federica; Coltelli, Luigi; De Giorgi, Ugo; Ferro, Antonella; Garrone, Ornella; Giordano, Monica; Landucci, Elisabetta; Mazzotta, Marco; Moretti, Gabriella; Palumbo, Raffaella; Pepe, Francesca Fulvia; Vici, Patrizia
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
BREAST
IF7.9
2024-04-011
OAAI
Freyer, Gilles; Martinez-Janez, Noelia; Kukielka-Budny, Bozena; Ulanska, Malgorzata; Bourgeois, Hugues; Munoz, Montserrat; Morales, Serafin; Calero, Juan Bayo; Cortesi, Laura; Pinter, Tamas; Palacova, Marketa; Cherciu, Nelli; Petru, Edgar; Ettl, Johannes; de Almeida, Cecilia; Villanova, Gustavo; Raymond, Romain; Minh, Christine Ta Thanh; Rodrigues, Ana; Cazzaniga, Marina E.
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
JNCI CANCER SPECTRUM
IF4.1
2023-12-190
OAAI
Cazzaniga, Marina Elena; Ademuyiwa, Foluso; Petit, Thierry; Tio, Joke; Generali, Daniele; Ciruelos, Eva M.; Califaretti, Nadia; Poirier, Brigitte; Ardizzoia, Antonio; Hoenig, Arnd; Lex, Benno; Mouret-Reynier, Marie-Ange; Giesecke, Dagmar; Isambert, Nicolas; Masetti, Ricardo; Pitre, Lacey; Wrobel, Denise; Augereau, Paule; Milani, Manuela; Rask, Sara; Solbach, Christine; Pritzker, Laura; Noubir, Sanaa; Parissenti, Amadeo; Trudeau, Maureen E.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
FRONTIERS IN ONCOLOGY
IF3.3
2023-10-264
OAAI
Cazzaniga, Marina Elena; Ciaccio, Antonio; Danesi, Romano; Duhoux, Francois P.; Girmenia, Corrado; Zaman, Kalhil; Lindman, Henrik; Luppi, Fabrizio; Mavroudis, Dimitrios; Paris, Ida; Olubukola, Ayodele; Samreen, Ahmed; Schem, Christian; Singer, Christian; Snegovoy, Anton
New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR plus )/human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Cogliati, V.; Rossi, E.; Turla, A.; Ambroggi, M.; Berardi, R.; Borella, F.; Coltelli, L.; De Giorgi, U. F. F.; Ferro, A.; Garrone, O.; Giordano, M.; Landucci, E.; Mazzotta, M.; Moretti, G.; Palumbo, R.; Vici, P.; Zustovich, F.; Riva, F.; Capici, S.; Cazzaniga, M. E.
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
SCIENTIFIC REPORTS
IF3.9
2023-07-283
OAAI
Trevisan, B.; Pepe, F. F.; Vallini, I.; Montagna, E.; Amoroso, D.; Berardi, R.; Butera, A.; Cagossi, K.; Cavanna, L.; Ciccarese, M.; Cinieri, S.; Cretella, E.; De Conciliis, E.; Febbraro, A.; Ferrau, F.; Ferzi, A.; Baldelli, A.; Fontana, A.; Gambaro, A. R.; Garrone, O.; Gebbia, V.; Generali, D.; Gianni, L.; Giovanardi, F.; Grassadonia, A.; Leonardi, V.; Sarti, S.; Musolino, A.; Nicolini, M.; Putzu, C.; Riccardi, F.; Santini, D.; Sarobba, M. G.; Schintu, M. G.; Scognamiglio, G.; Spadaro, P.; Taverniti, C.; Toniolo, D.; Tralongo, P.; Turletti, A.; Valenza, R.; Valerio, M. R.; Vici, P.; Clivio, L.; Torri, V.; Cazzaniga, M. E.

研究方向

暂未获取到该数据
O
Ornella Garrone
H 指数:38论文数:417被引数:7,146
D
Daniele Generali
H 指数:58论文数:534被引数:1.3万
S
Serena Capici
H 指数:11论文数:35被引数:501
I
Ida Paris
H 指数:26论文数:152被引数:1,970
P
Patrizia Vici
H 指数:44论文数:394被引数:7,836
M
Maria Grazia Cerrito
H 指数:23论文数:76被引数:1,475
M
Maria Rosaria Valerio
H 指数:27论文数:181被引数:2,554
B
Bernardo Bonanni
H 指数:72论文数:485被引数:2.3万
A
Alberto Zambelli
H 指数:46论文数:448被引数:8,599
R
Rossana Berardi
H 指数:63论文数:1,192被引数:1.5万